Literature DB >> 7035562

Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.

M S Edwards, D L Kasper, H J Jennings, C J Baker, A Nicholson-Weller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7035562

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  78 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Capsular sialic acid limits C5a production on type III group B streptococci.

Authors:  S Takahashi; Y Aoyagi; E E Adderson; Y Okuwaki; J F Bohnsack
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

Review 3.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  O-Acetylation of sialic acid on Group B Streptococcus inhibits neutrophil suppression and virulence.

Authors:  Shannon Weiman; Satoshi Uchiyama; Feng-Ying C Lin; Donald Chaffin; Ajit Varki; Victor Nizet; Amanda L Lewis
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

6.  Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae.

Authors:  Lakshmi Rajagopal; Anthony Vo; Aurelio Silvestroni; Craig E Rubens
Journal:  Mol Microbiol       Date:  2006-09-27       Impact factor: 3.501

7.  Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression.

Authors:  D O Chaffin; L M Mentele; C E Rubens
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

8.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.

Authors:  M R Wessels; C E Rubens; V J Benedí; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Characterization of CMP-N-acetylneuraminic acid synthetase of group B streptococci.

Authors:  R F Haft; M R Wessels
Journal:  J Bacteriol       Date:  1994-12       Impact factor: 3.490

10.  Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis.

Authors:  R C Arduino; K Jacques-Palaz; B E Murray; R M Rakita
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.